Molecular Dynamics Simulations Reveal Membrane Interactions for Poorly Water-Soluble Drugs: Impact of Bile Solubilization and Drug Aggregation
article
OA: hybrid
CC0
Abstract
Molecular transport mechanisms of poorly soluble hydrophobic drug compounds to lipid membranes were investigated using molecular dynamics (MD) simulations. The model compound danazol was used to investigate the mechanism(s) by which bile micelles delivered it to the membrane. The interactions between lipid membrane and pure drug aggregates-in the form of amorphous aggregates and nanocrystals-were also studied. Our simulations indicate that bile micelles formed in the intestinal fluid may facilitate danazol incorporation into cellular membranes through two different mechanisms. The micelle may be acting as: i) a shuttle that presents the danazol directly to the membrane or ii) an elevator that moves the solubilized danazol with it as the colloidal structure itself becomes incorporated and solubilized within the membrane. The elevator hypothesis was supported by complementary lipid monolayer adsorption experiments. In these experiments, colloidal structures formed with simulated intestinal fluid were observed to rapidly incorporate into the monolayer. Simulations of membrane interaction with drug aggregates showed that both the amorphous aggregates and crystalline nanostructures incorporated into the membrane. However, the amorphous aggregates solubilized more quickly than the nanocrystals into the membrane, thereby improving the danazol absorption.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs 1995
- A Comparison of the Solubility of Danazol in Human and Simulated Gastrointestinal Fluids 2000
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers 2012
- Impact of Polymers on the Precipitation Behavior of Highly Supersaturated Aqueous Danazol Solutions 2014
References (66)
- A Comparison of the Solubility of Danazol in Human and Simulated Gastrointestinal Fluids via openalex
- Impact of Polymers on the Precipitation Behavior of Highly Supersaturated Aqueous Danazol Solutions via openalex
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers via openalex
- Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs via openalex
- doi:10.1002/jps.24603 via openalex
- doi:10.1016/0005-2760(74)90253-7 via openalex
- doi:10.1016/j.bpj.2015.04.010 via openalex
- doi:10.1063/1.4823234 via openalex
- doi:10.1021/ct100494z via openalex
- doi:10.1021/jp505332p via openalex
- doi:10.1002/cphc.200600527 via openalex
- doi:10.14227/dt170310p6 via openalex
- doi:10.1016/j.bbamem.2011.07.022 via openalex
- doi:10.2174/138161209788682479 via openalex
- doi:10.1016/j.softx.2015.06.001 via openalex
- doi:10.1021/jp036508g via openalex
- doi:10.1021/la803361y via openalex
- doi:10.1021/acs.molpharmaceut.5b00704 via openalex
- doi:10.1016/j.plipres.2016.12.001 via openalex
- doi:10.1016/j.ijpharm.2008.09.027 via openalex
- doi:10.1016/j.jconrel.2005.11.010 via openalex
- doi:10.1016/s0378-5173(00)00526-3 via openalex
- doi:10.1021/acs.langmuir.6b03008 via openalex
- W2286884653 via openalex
- doi:10.1016/j.ejps.2013.10.015 via openalex
- doi:10.1186/1758-2946-4-17 via openalex
- doi:10.1016/0021-9991(77)90121-8 via openalex
- doi:10.1063/1.2825620 via openalex
- doi:10.1016/j.jmgm.2005.12.005 via openalex
- doi:10.1021/acs.jctc.5b00209 via openalex
- doi:10.1021/jp071097f via openalex
- doi:10.1039/c6sm00763e via openalex
- doi:10.1039/b813853m via openalex
- doi:10.1021/ct300342n via openalex
- doi:10.1186/1477-3155-12-5 via openalex
- doi:10.1016/j.jcis.2019.06.045 via openalex
- doi:10.1039/c9nr09947f via openalex
- W6653749852 via openalex
- W6657350852 via openalex
- doi:10.1038/s41598-017-06445-z via openalex
- doi:10.1021/acs.jpcb.7b08622 via openalex
- doi:10.1016/j.ejps.2019.104967 via openalex
- doi:10.1080/10717544.2019.1704940 via openalex
- doi:10.1021/acs.molpharmaceut.8b00064 via openalex
- doi:10.1021/jacs.9b04387 via openalex
- doi:10.1016/0166-1280(93)87060-q via openalex
- doi:10.3390/pharmaceutics11030129 via openalex
- doi:10.1208/s12249-018-1289-4 via openalex
- doi:10.1208/s12248-012-9445-3 via openalex
- doi:10.1021/ct2005193 via openalex
- doi:10.1016/0378-5173(94)90459-6 via openalex
- doi:10.1021/jp212503e via openalex
- doi:10.1007/s11095-012-0795-4 via openalex
- doi:10.1093/nar/gkr288 via openalex
- doi:10.1021/acs.molpharmaceut.0c00588 via openalex
- doi:10.1021/acs.molpharmaceut.8b00699 via openalex
- doi:10.1016/j.sjbs.2015.03.007 via openalex
- doi:10.1080/21553769.2013.879925 via openalex
- doi:10.1002/jcc.20035 via openalex
- doi:10.1080/00268978400101201 via openalex
- doi:10.1021/acs.molpharmaceut.8b00811 via openalex
- doi:10.1021/mp9000662 via openalex
- doi:10.1007/s11095-013-1083-7 via openalex
- doi:10.1023/a:1014322611370 via openalex
- doi:10.1103/physreva.31.1695 via openalex
- doi:10.1063/1.328693 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:10:27.824888+00:00
License: CC0
· commercial use OK